نتایج جستجو برای: induced liver injury dili

تعداد نتایج: 1452682  

2014
Mark I. Avigan Einar S. Bjornsson Markku Pasanen Charles Cooper Raul J. Andrade Paul B. Watkins James H. Lewis Michael Merz

A workshop was convened to discuss best practices for the assessment of drug-induced liver injury (DILI) in clinical trials. In a breakout session, workshop attendees discussed necessary data elements and standards for the accurate measurement of DILI risk associated with new therapeutic agents in clinical trials. There was agreement that in order to achieve this goal the systematic acquisition...

2014
Ke Yu Xingchao Geng Minjun Chen Jie Zhang Bingshun Wang Katarina Ilic Weida Tong

Drug-induced liver injury (DILI) is complicated and difficult to predict. It has been observed that drugs with extensive hepatic metabolism have a higher likelihood of causing DILI. Cytochrome P450 (P450) enzymes are primarily involved in hepatic metabolism. Identifying the associations of DILI with drugs that are P450 substrates, inhibitors, or inducers will be extremely helpful to clinicians ...

Journal: :Gut 2009
S Verma N Kaplowitz

Drug-induced liver injury (DILI) is increasingly being recognised as a significant cause of both acute and chronic liver disease. The most commonly implicated agents are paracetamol, antimicrobials, non-steroidal anti-inflammatory drugs, statins, isoniazid and herbal remedies. Drug-induced hepatotoxicity is generally idiosyncratic in nature. The pathogenesis of DILI remains enigmatic, but invol...

2017
Keith Glenn Patrick Chen Mustafa Musleh Rao Pallivi Melissa Grilliot

Importance. As Rivaroxaban has increased in popularity, it has been accompanied with a growing body of evidence displaying its ability to cause drug induced liver injury (DILI). Observation. A 74-year-old Caucasian female developed Rivaroxaban DILI two weeks after finishing a 14-day course. The patient was symptomatic and jaundiced with elevated transaminases and hyperbilirubinemia with normal ...

2013
Nury M. Steuerwald David M. Foureau H. James Norton Jie Zhou Judith C. Parsons Naga Chalasani Robert J. Fontana Paul B. Watkins William M. Lee K. Rajender Reddy Andrew Stolz Jayant Talwalkar Timothy Davern Dhanonjoy Saha Lauren N. Bell Huiman Barnhart Jiezhun Gu Jose Serrano Herbert L. Bonkovsky

UNLABELLED Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the United-States. The aim of the study was to describe serum immune profiles associated with acute DILI, to investigate whether there are profiles associated with clinical features or types of DILI and/or with prognosis, and to assess temporal changes in levels. Twenty-seven immune analytes were meas...

2011
Getnet Yimer Nobuhisa Ueda Abiy Habtewold Wondwossen Amogne Akira Suda Klaus-Dieter Riedel Jürgen Burhenne Getachew Aderaye Lars Lindquist Eyasu Makonnen Eleni Aklillu

BACKGROUND Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury (DILI) has not been yet studied. We performed a prospective case-control association study to identify the incidence, pharmacogenetic, pharmacokinetic and biochemical predictors for anti-tubercular and antiretroviral d...

Journal: :Livers 2022

Herbal and dietary supplement (HDS) use has grown exponentially in the United States. Unfortunately, incidence of HDS-related liver injury proportionally increased. Despite potential for certain HDSs to cause clinically significant injury, they are not regulated by Food Drug Administration. Recent efforts have been made regulate but far removed from scrutiny prescription medications. Scant lite...

Journal: :Gastroenterologia y hepatologia 2012
Filipe Vilas-Boas Regina Gonçalves Manuel Sobrinho Simões Joanne Lopes Guilherme Macedo

Drug-induced liver injury (DILI) is a leading cause of liver failure and an important safety issue in drug development. Thalidomide is nowadays used for the treatment of several conditions including multiple myeloma (MM). Several adverse effects have been described but liver toxicity was seldom reported. We describe a case of thalidomide-induced hepatitis in a man treated for MM. The clinical s...

2015
Wan Soo Kim Sang Soo Lee Chang Min Lee Hong Jun Kim Chang Yoon Ha Hyun Jin Kim Tae Hyo Kim Woon Tae Jung Ok Jae Lee Jeong Woo Hong Hyun Seon You Hyun Chin Cho

BACKGROUND The risk of anti-tuberculosis (TB) drug-induced liver injury (DILI) in patients with chronic viral hepatitis (CVH) is not clear. The aim of this study was to investigate incidence and risk factors associated with TB DILI in CVH and non-CVH patients. METHODS Retrospectively, a total of 128 CVH patients who received anti-TB medication from January 2005 to February 2014 were reviewed....

2012
Yifeng Guo Yu Fan Jianxin Qiu Yong Liu Junwei Gao Fang Guo

Genetic polymorphisms in cytotoxic T lymphocyte-associated antigen 4 (CTLA4) play an influential role in graft rejection and the long-term clinical outcome of organ transplantation. We investigated the association of 5 CTLA4 single-nucleotide polymorphisms (SNPs) (rs733618 C/T, rs4553808 A/G, rs5742909 C/T, rs231775 A/G, and rs3087243 G/A) with drug-induced liver injury (DILI) in Chinese renal ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید